Cullinan Therapeutics (CGEM) TD Cowen 45th Annual Healthcare Conference summary

Strategic pipeline and clinical milestones

• 2025 is positioned as a pivotal year with multiple catalysts expected, including data readouts and study initiations.

• The pipeline includes five clinical-stage assets targeting both autoimmune diseases and cancer, with a focus on immune system modulation.

• CLN-978, a CD19xCD3 T cell engager, is being advanced in autoimmune diseases, with lupus data expected in Q4 and a rheumatoid arthritis study starting in Q2.

• Oncology programs include CLN-619 (MICA/B pathway antibody) with expansion cohort data in endometrial and cervical cancer due in Q2, and zipalertinib (EGFR exon 20 inhibitor) with pivotal data and NDA submission planned for mid to late year.

• Cash reserves exceed $600 million as of December, supporting ongoing and future development.

Market opportunity and competitive positioning

• CLN-978 is the first CD19 T cell engager to clear an IND in the U.S. for autoimmune diseases, providing a competitive edge.

• Large addressable markets exist in lupus (160,000 U.S. patients) and rheumatoid arthritis (1.7 million U.S. patients), with significant commercial potential.

• T cell engagers are positioned as more potent and flexible than monoclonal antibodies, and more accessible than CAR-T therapies.

• Off-the-shelf T cell engagers offer redosing flexibility and a favorable safety profile compared to CAR-T, with lower rates and grades of adverse events.

• Community-based administration is emphasized as a key advantage for broad adoption, overcoming referral and logistical barriers.

Clinical and scientific insights

• T cell engagers and CAR-T therapies both offer superior efficacy over monoclonal antibodies, but T cell engagers provide greater convenience and safety.

• Depth of B-cell depletion is more critical than duration for achieving durable responses in autoimmune diseases.

• Treatment-free remission rates of 20–30% with grade 1–2 CRS are considered the minimum commercially viable profile for lupus.

• Patient-free intervals of 9–12 months are seen as highly clinically significant and commercially attractive.

• In oncology, T cell engagers have demonstrated survival benefits over monoclonal antibodies and comparable efficacy to CAR-T in certain settings.